ZA961460B - Vaccine compositions - Google Patents

Vaccine compositions

Info

Publication number
ZA961460B
ZA961460B ZA961460A ZA961460A ZA961460B ZA 961460 B ZA961460 B ZA 961460B ZA 961460 A ZA961460 A ZA 961460A ZA 961460 A ZA961460 A ZA 961460A ZA 961460 B ZA961460 B ZA 961460B
Authority
ZA
South Africa
Prior art keywords
vaccine compositions
vaccine
compositions
Prior art date
Application number
ZA961460A
Other languages
English (en)
Inventor
Pierre Hauser
Nathalie Marie-Josephin Garcon
Pierre Desmons
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10770292&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA961460(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of ZA961460B publication Critical patent/ZA961460B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA961460A 1995-02-25 1996-02-23 Vaccine compositions ZA961460B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9503863.4A GB9503863D0 (en) 1995-02-25 1995-02-25 Vaccine compositions

Publications (1)

Publication Number Publication Date
ZA961460B true ZA961460B (en) 1996-08-29

Family

ID=10770292

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA961460A ZA961460B (en) 1995-02-25 1996-02-23 Vaccine compositions

Country Status (36)

Country Link
US (1) US5972346A (pl)
EP (1) EP0810877B1 (pl)
JP (1) JP3881015B2 (pl)
KR (1) KR100365373B1 (pl)
CN (1) CN1101225C (pl)
AP (1) AP766A (pl)
AR (1) AR002279A1 (pl)
AT (1) ATE209045T1 (pl)
AU (1) AU695921B2 (pl)
BG (1) BG101851A (pl)
BR (1) BR9607458A (pl)
CA (1) CA2212552C (pl)
CZ (1) CZ288417B6 (pl)
DE (1) DE69617211T2 (pl)
DK (1) DK0810877T3 (pl)
EA (1) EA199700126A1 (pl)
ES (1) ES2166879T3 (pl)
FI (1) FI118118B (pl)
GB (1) GB9503863D0 (pl)
HK (1) HK1004117A1 (pl)
HU (1) HU224832B1 (pl)
IL (1) IL117249A (pl)
MA (1) MA23814A1 (pl)
MX (1) MX9706450A (pl)
MY (1) MY113428A (pl)
NO (1) NO319394B1 (pl)
NZ (1) NZ302674A (pl)
OA (1) OA10612A (pl)
PL (1) PL182679B1 (pl)
PT (1) PT810877E (pl)
SA (1) SA96160633B1 (pl)
SK (1) SK115097A3 (pl)
TR (1) TR199700849T1 (pl)
TW (1) TW467745B (pl)
WO (1) WO1996026741A1 (pl)
ZA (1) ZA961460B (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620414B2 (en) * 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US6488934B1 (en) * 1995-02-25 2002-12-03 Smithkline Beecham Biologicals S.A. Hepatitis B vaccine
US20010014331A1 (en) * 1996-11-07 2001-08-16 Smithkline Beecham Biologicals S.A. Acellular pertussis vaccine with diphthriae-and tetanus-toxoids
GB9809507D0 (en) * 1998-05-01 1998-07-01 Smithkline Beecham Biolog Novel composition
US20030049268A1 (en) 1998-05-01 2003-03-13 Smithkline Beecham Biologicals S.A. Novel composition
US8574599B1 (en) 1998-05-22 2013-11-05 Ottawa Hospital Research Institute Methods and products for inducing mucosal immunity
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
PL201482B1 (pl) * 1998-10-16 2009-04-30 Smithkline Beecham Biolog Sposoby wytwarzania kompozycji szczepionki oraz kompozycja szczepionki
CU22871A1 (es) * 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
WO2000037104A1 (en) * 1998-12-23 2000-06-29 Merck & Co., Inc. Improved recombinant hepatitis b surface antigen
AU764969B2 (en) 1999-04-19 2003-09-04 Smithkline Beecham Biologicals (Sa) Vaccines
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
CU23031A1 (es) * 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
BE1016991A6 (fr) * 2005-02-16 2007-11-06 Chiron Corp Composition d'adjuvants comprenant du phosphate d'aluminium et du 3d-mpl.
EA014314B1 (ru) * 2005-08-02 2010-10-29 Новартис Вэксинес Энд Дайэгностикс Срл Пониженная интерференция между маслосодержащими адъювантами и антигенами, содержащими поверхностно-активные вещества
US8697087B2 (en) 2005-11-04 2014-04-15 Novartis Ag Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
PT2368572T (pt) 2005-11-04 2020-06-16 Seqirus Uk Ltd Vacinas com adjuvante dotadas de antigénios não-virião preparados a partir de vírus da gripe cultivado em cultura celular
NZ592713A (en) 2005-11-04 2012-12-21 Novartis Vaccines & Diagnostic Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9
NZ594482A (en) 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
CN100415294C (zh) * 2005-12-23 2008-09-03 中国农业大学 一种治疗和/或预防乙肝的药物
US20110027314A1 (en) 2006-01-27 2011-02-03 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Influenza Vaccines Containing Hemagglutinin and Matrix Proteins
ES2536426T3 (es) 2006-03-23 2015-05-25 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
EP1862176A1 (de) * 2006-05-31 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Ein Verfahren zur Herstellung einer Impfzusammensetzung
EP1862177A1 (de) * 2006-06-01 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Ein Verfahren zur Herstellung einer Impfzusammensetzung
EP2035035A2 (en) 2006-06-09 2009-03-18 Novartis AG Immunogenic compositions for streptococcus agalactiae
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
ES2694805T7 (es) 2006-09-11 2021-10-21 Seqirus Uk Ltd Fabricación de vacunas contra virus de la gripe sin usar huevos
EP2121011B1 (en) 2006-12-06 2014-05-21 Novartis AG Vaccines including antigen from four strains of influenza virus
DK2185191T3 (da) 2007-06-27 2012-12-03 Novartis Ag Influenzavacciner med lavt indhold af tilsætningsstoffer
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
CA2710480A1 (en) 2007-12-24 2009-07-02 Novartis Ag Assays for adsorbed influenza vaccines
ES2918381T3 (es) 2009-07-15 2022-07-15 Glaxosmithkline Biologicals Sa Composiciones de proteína F de VRS y métodos para producir las mismas
DK2667892T3 (da) 2011-01-26 2019-05-13 Glaxosmithkline Biologicals Sa RSV-vaccineringsprogram
US9452212B2 (en) 2011-04-14 2016-09-27 Dynavax Technologies Corporation Methods and compositions for eliciting an immune response against hepatitis B virus
JP2014519819A (ja) 2011-05-13 2014-08-21 ノバルティス アーゲー 融合前ｒｓｖｆ抗原
BR112017028011A2 (pt) 2015-06-26 2018-08-28 Seqirus Uk Ltd vacinas de gripe correspondentes antigenicamente

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ES2109921T3 (es) * 1989-07-25 1998-02-01 Smithkline Beecham Biolog Nuevos antigenos y procedimientos para su preparacion.
EP0835639A3 (en) * 1991-05-29 1999-04-07 Origin Medsystems, Inc. Retraction apparatus for endoscopic surgery
MY111880A (en) * 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
SK280702B6 (sk) * 1992-05-23 2000-06-12 Smithkline Beecham Biologicals S. A. Kombinovaný očkovací prostriedok obsahujúci povrch
DK0812593T4 (da) * 1993-03-23 2008-05-13 Smithkline Beecham Biolog Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryllipid-A
GB9311536D0 (en) * 1993-06-04 1993-07-21 Unilever Plc Hot soluble low density extractable food product

Also Published As

Publication number Publication date
FI973457A (fi) 1997-08-22
IL117249A0 (en) 1996-06-18
HUP9801242A1 (hu) 1998-08-28
IL117249A (en) 2000-11-21
KR19980702480A (ko) 1998-07-15
AU695921B2 (en) 1998-08-27
MX9706450A (es) 1998-07-31
EP0810877A1 (en) 1997-12-10
PL321966A1 (en) 1998-01-05
CA2212552A1 (en) 1996-09-06
WO1996026741A1 (en) 1996-09-06
AU4878096A (en) 1996-09-18
NZ302674A (en) 1999-01-28
JPH11501018A (ja) 1999-01-26
SA96160633B1 (ar) 2005-10-15
AR002279A1 (es) 1998-03-11
PT810877E (pt) 2002-04-29
DE69617211T2 (de) 2002-07-25
KR100365373B1 (ko) 2003-07-07
TR199700849T1 (xx) 1998-01-21
BR9607458A (pt) 1998-06-30
HK1004117A1 (en) 1998-11-20
NO973873L (no) 1997-08-22
NO319394B1 (no) 2005-08-08
CZ288417B6 (en) 2001-06-13
DK0810877T3 (da) 2002-02-25
CA2212552C (en) 2006-07-11
FI973457A0 (fi) 1997-08-22
GB9503863D0 (en) 1995-04-19
CN1176604A (zh) 1998-03-18
DE69617211D1 (en) 2002-01-03
AP766A (en) 1999-09-17
EP0810877B1 (en) 2001-11-21
PL182679B1 (pl) 2002-02-28
TW467745B (en) 2001-12-11
OA10612A (en) 2002-08-29
JP3881015B2 (ja) 2007-02-14
ATE209045T1 (de) 2001-12-15
ES2166879T3 (es) 2002-05-01
NO973873D0 (no) 1997-08-22
US5972346A (en) 1999-10-26
AP9701060A0 (en) 1997-10-31
MY113428A (en) 2002-02-28
EA199700126A1 (ru) 1998-02-26
CN1101225C (zh) 2003-02-12
BG101851A (en) 1998-04-30
FI118118B (fi) 2007-07-13
MA23814A1 (fr) 1996-10-01
HU224832B1 (en) 2006-03-28
HUP9801242A3 (en) 2000-08-28
SK115097A3 (en) 1998-02-04
CZ267497A3 (cs) 1998-02-18

Similar Documents

Publication Publication Date Title
IL118004A0 (en) Vaccine compositions
IL117249A0 (en) Vaccine compositions
EG20993A (en) Cleasing compositions
EG20989A (en) Cleasing compositions
IL109056A0 (en) Vaccine compositions
GB9613043D0 (en) Improved compositions
GB9500577D0 (en) Compositions
GB9511366D0 (en) Novel formulations
GB9504996D0 (en) Compositions
HU9600207D0 (en) Vaccine compositions
GB9516371D0 (en) Compositions
ZA961514B (en) Novel compositions
GB9326425D0 (en) Vaccine compositions
GB9515805D0 (en) Compositions
GB9508785D0 (en) Novel compositions
GB9614618D0 (en) Vaccine compositions
HUP9601550A2 (en) Particulale compositions
GB9604856D0 (en) Compositions
GB9510719D0 (en) Novel compositions
GB9519109D0 (en) Compositions
GB9526433D0 (en) Vaccine component
GB9517113D0 (en) Novel compositions
GB9403417D0 (en) Vaccine compositions
GB9601739D0 (en) Vaccine Compositions
GB9425980D0 (en) Vaccine compositions